Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for generating antigen-specific effector T cells

A specific, cellular technology that is used in biochemical equipment and methods, receptors/cell surface antigens/cell surface determinants, other methods of inserting foreign genetic material, etc.

Inactive Publication Date: 2009-04-22
ARGOS THERAPEUTICS INC
View PDF3 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Thus, there exists a long-felt unmet need for the efficient transfer of antigen-specific TCR function to T cells that does not require retroviral vectors or other forms of transfection that may result in genomic alterations of the subject

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for generating antigen-specific effector T cells
  • Methods for generating antigen-specific effector T cells
  • Methods for generating antigen-specific effector T cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] While the making and using of various embodiments of the invention are described in detail below, it should be appreciated that the invention provides many advantageous inventive concepts that can be implemented in a wide variety of specific contexts. The specific embodiments described herein are merely illustrative of specific ways to make and use the invention, and do not limit the scope of the invention.

[0027] To facilitate the understanding of the present invention, terms defined herein have meanings commonly understood by those skilled in the art related to the present invention. Words such as "a", "an" and "the" do not denote only a single individual, but include the general class to which particular embodiments may be used for illustration. The terminology herein is used to describe particular embodiments of the invention, but their usage does not delimit the invention unless stated in the specification. For example, the term "a cell" includes a plurality of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to T cells transiently transfected with RNA, especially RNA encoding a T cell receptor and / or FoxP3, and methods of transfecting T cells with RNA by electroporation. Compositions of the invention include an effector T cell transiently transfected with RNA encoding a T cell receptor (TCR) specific for an antigen, wherein the T cell demonstrates effector function specific for cells presenting the antigen in complex with an MHC molecule. Treg cells comprising an exogenous RNA encoding FoxP3 are also provided. The transfected T cells are useful for immunotherapy, particularly in the treatment of tumors, pathogen infection, autoimmune disease, transplant rejection and graft versus host disease.

Description

technical field [0001] The present invention relates to T cells transiently transfected with RNA - in particular RNA encoding T cell receptors and / or FoxP3 - and methods of transfecting T cells with RNA by electroporation. The transfected T cells can be used for immunotherapy, especially for the treatment of tumors, pathogenic infections, autoimmune diseases, transplantation rejection and graft-versus-host disease. Background technique [0002] Cytotoxic T lymphocytes (CTLs) play a major role in tumor control and thus have great importance in the cellular regimen of cancer immunotherapy [19]. Earlier attempts at the adoptive transfer of tumor-infiltrating lymphocytes (TILs) were unsatisfactory because the transferred cells were often nonspecific and did not persist for extended periods of time, most likely due to the possible anergy phenotype of such TILs (anergic phenotype) or unable to self-guid to the tumor site [10,11]. Adoptive transfer of in vitro expanded autologous...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/82C12N15/87C07K14/705C12N5/06A61K39/00C12N5/0783
CPCC07K14/7051A61K2039/5156C12N5/0636A61K39/00A61P31/00A61P35/00A61P37/02A61P37/06C07K14/705C12N15/89
Inventor G·舒勒J·德里尼尔斯·沙夫特
Owner ARGOS THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products